Alexander Disease with Features of Both Frontal and Bulbospinal Involvement
Neurol 91:e396-e397, Nam,T-S.,et al, 2018
Glutamate Receptor D2 Serum Antibodies in Pediatric Opsoclonus Myoclonus Ataxia Syndrome
Neurol 91:e714-e723, Berridge, G.,et al, 2018
Clnicopathologic Conference Anti-N-Methyl-D-Aspartate (NMDA) Receptor Encephalitis
NEJM 379:870-878, CASE 27-2018, 2018
Atypical Parkinsonian Syndromes: A General Neurologists Perspective
Eur J Neurol 25:41-58, Deutschlander, A.B.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Dual Antiplatelet Therapy with Aspirin and Clopidogrel for Acute High Risk Transient Ischaemic Attack and Minor Ischaemic Stroke: A Clinical Practice Guideline
BMJ 363:k5130, Prasad, K.,et al, 2018
Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018
Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018
Safety of Lumbar Puncture Performed on Dual Antiplatelet Therapy
Mayo Clin Proc 93:627-629, Carabenciov,I.D.,et al, 2018
Clinicopathologic Conference, Paroxysmal Nocturnal Hemoglobinuria
NEJM 377:2581-2590, Case 40-2017, 2017
Glial Fibrillary Acidic Protein Immunoglobulin G as Biomarker of Autoimmune Astrocytopathy: Analysis of 102 Patients
Ann Neurol 81:298-309, Flanagan, E.P.,et al, 2017
Maternal Use of antiepileptic Agents During Pregnancy and Major Congenital Malformations in Children
JAMA 318:1700-1701, Bromley, R.L.,et al, 2017
Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017
Clinicopathologic Conference, Copper Deficiency Myelopathy
NEJM 377:1977-1984, Case 35-2017, 2017
An 82-year-old man with Worsening Gait
Neurol 89:e246-e252, Chew, S.,et al, 2017
Low-Dose Aspirin and Risk of Intracranial Bleeds
Neurol 89:2280-2287, Soriano, L.C.,et al, 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Long-Term Benefit of Enzyme Replacement Therapy in Pompe Disease
Neurol 89:2365-2373, Kuperus, E.,et al, 2017
Paraneoplastic and Autoimmune Encephalitis
UptoDate July, Dalmau, J.,et al, 2017
Autoimmune Limbic Encephalitis Associated with Type 1 Diabetes Mellitus
J Clin Res Pediatr Endocrinol 9:387-388, Akin,O.,et al, 2017
Association of Antithrombotic Drug Use with Subdural Hematoma Risk
JAMA 317:836-846, Gaist, D.,et al, 2017
Investigations in GABA? Receptor Antibody-Associated Encephalitis
Neurol 88:1012-1020,1010, Spatola, M.,et al, 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Anticoagulant and Antiplatelet Use in Seniors with Chronic Subdural Hematoma
Neurol 88:1889-1893, Nathan, S.,et al, 2017
Intractable Epilepsy and Progressive Cognitive Decline in a Young Man
JAMA Neurol 74:737-740, Cohen, A.L.,et al, 2017
Older Patients Should Take PPIs to Cut Risk of Bleed From Aspirin, Study Says
BMJ 357:J2865, Mayor, S., 2017
An Older Man with Memory Impairment and Convulsions
BMJ 358:J2824, Zhao, X.,et al, 2017
A New Potential Biomarker for Dementia with Lewy Bodies
Neurol 89:318-326, Donadio, V.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
JAMA Neurol 74:60-66, Robeson, K.R.,et al, 2017
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Stroke Outcomes with use of Antithrombotics within 24 hours after Recanalization Treatment
Neurol 87:996-1002, Jeong, H.G.,et al, 2016
Diagnosis and Treatment of Tourette Syndrome
Neurol 87:e65-e67, Hirschtritt, M.E.,et al, 2016
A 52-year-old Man with Diplopia and Ataxia
Neurol 87:e140-e143, Bradshaw, M.J.,et al, 2016
Tranexamic Acid-Associated Seizures: Causes and Treatment
Ann Neurol 79:18-26, Lecker, I.,et al, 2016
Bright Tongue Sign in Pompe Disease
Neurol 86:401, Karam, C., 2016
Natalizumab-Related PML 2 Weeks after Negative Anti-JCV Antibody Assay
Neurol 86:484-486, Gagne, M.S.,et al, 2016
Embolic Stroke, Atrial Fibrillation, and Microbleeds
Stroke 47:904-907, Diener, H-C.,et al, 2016
Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome
Ann Neurol 79:560-568, Park, J.M.,et al, 2016
Rituximab Treatment for Autoimmune Limbic Encephalitis in an Institutional Cohort
Neurol 86:1683-1691,1655, Lee, W.J.,et al, 2016
Tocilizumab for Induction and Maintenance of Remission in Giant Cell Arteritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 387:1921-1927,1882, Villiger, P.M.,et al, 2016
A 38-Year-Old Man with Respiratory Failure and Progressive Leg Weakness
Neurol 86:e190-e194, McIntosh, P. & Karam, C., 2016
Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016
Risk of Cerebral Venous Thrombosis in Obese Women
JAMA Neurol 73:579-584, Zuurbier, S.M.,et al, 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016